Johnson & Johnson to start human testing on Ebola vaccine

 
Emma Haslett
Follow Emma
US PHARMA giant Johnson & Johnson announced today that it would begin human trials of its Ebola vaccine in January.

The company said it would spend $200m (£124m) on speeding up its research programme, and begin testing in America, Africa and Europe early next year.

The vaccine combines a formula from one of its subsidiaries, Janssen, with one from Danish pharma firm Bavarian Nordic.

It targets the Zaire strain of the disease, currently affecting coun­tries in West Africa, and has “shown promising results”, said the company.

Related articles